Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia
Background: Medical resources, especially blood products, were in short supply during the COVID-19. Less intensive therapy with hypomethylating agents/venetoclax (VEN) seems an effective treatment option for patients with acute myeloid leukemia (AML). Objectives: To retrospectively analyze the effic...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-01-01
|
| Series: | Therapeutic Advances in Hematology |
| Online Access: | https://doi.org/10.1177/20406207241311776 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841557286620758016 |
|---|---|
| author | Xuezhu Xu Rui Liu Hongli Chen Ruoyu Yang Gongzhizi Gao Aili He Fangxia Wang |
| author_facet | Xuezhu Xu Rui Liu Hongli Chen Ruoyu Yang Gongzhizi Gao Aili He Fangxia Wang |
| author_sort | Xuezhu Xu |
| collection | DOAJ |
| description | Background: Medical resources, especially blood products, were in short supply during the COVID-19. Less intensive therapy with hypomethylating agents/venetoclax (VEN) seems an effective treatment option for patients with acute myeloid leukemia (AML). Objectives: To retrospectively analyze the efficacy and safety of VEN combined with azacitidine (AZA) in young adult patients with newly diagnosed (ND) AML. Design: This was a retrospective study. Methods: The clinical data of 25 AML patients treated with the VEN + AZA regimen from January 2021 to December 2023 at our center were collected, compared with a randomized historical study cohort that was administered intensive chemotherapy (IC) from January 2018 to December 2019. Results: No rate of complete remission/complete remission with incomplete count recovery differences observed between the two arms reached statistical significance. Compared to traditional IC, minimal residual disease (MRD)-negative remission was achieved more quickly in patients treated with VEN + AZA regimens (after cycle 1: 8% in the IC group vs 56% in the VEN group, p = 0.0004; after cycle 2: 16% in the IC group vs 72% in the VEN group, p = 0.0001), especially in those AML patients who had a poor prognosis. The dependency of transfusion of red blood cell (RBC) and platelets during induction treatment was significantly lower in the VEN + AZA group (RBC: p = 0.0269; platelet: p = 0.0054). Compared with the standard IC, the incidence rate of non-hematological adverse events in VEN + AZA group was significantly decreased (infection: 100% vs 20%, p = 0.0001; gastrointestinal side effects: 48% vs 12%, p = 0.0055). The total hospitalization cost of the VEN group was significantly less than that of the IC group ( p = 0.0395). Conclusion: In conclusion, our study indicated that VEN + AZA with a higher MRD-negative remission rate and less toxic appeared to be a therapy option for young patients with ND AML. However, further well-designed studies with larger numbers of patients are needed to confirm the benefits of VEN + AZA in this population. |
| format | Article |
| id | doaj-art-90285818077b4648bbeaae7e4200584a |
| institution | Kabale University |
| issn | 2040-6215 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Hematology |
| spelling | doaj-art-90285818077b4648bbeaae7e4200584a2025-01-06T14:03:31ZengSAGE PublishingTherapeutic Advances in Hematology2040-62152025-01-011610.1177/20406207241311776Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemiaXuezhu XuRui LiuHongli ChenRuoyu YangGongzhizi GaoAili HeFangxia WangBackground: Medical resources, especially blood products, were in short supply during the COVID-19. Less intensive therapy with hypomethylating agents/venetoclax (VEN) seems an effective treatment option for patients with acute myeloid leukemia (AML). Objectives: To retrospectively analyze the efficacy and safety of VEN combined with azacitidine (AZA) in young adult patients with newly diagnosed (ND) AML. Design: This was a retrospective study. Methods: The clinical data of 25 AML patients treated with the VEN + AZA regimen from January 2021 to December 2023 at our center were collected, compared with a randomized historical study cohort that was administered intensive chemotherapy (IC) from January 2018 to December 2019. Results: No rate of complete remission/complete remission with incomplete count recovery differences observed between the two arms reached statistical significance. Compared to traditional IC, minimal residual disease (MRD)-negative remission was achieved more quickly in patients treated with VEN + AZA regimens (after cycle 1: 8% in the IC group vs 56% in the VEN group, p = 0.0004; after cycle 2: 16% in the IC group vs 72% in the VEN group, p = 0.0001), especially in those AML patients who had a poor prognosis. The dependency of transfusion of red blood cell (RBC) and platelets during induction treatment was significantly lower in the VEN + AZA group (RBC: p = 0.0269; platelet: p = 0.0054). Compared with the standard IC, the incidence rate of non-hematological adverse events in VEN + AZA group was significantly decreased (infection: 100% vs 20%, p = 0.0001; gastrointestinal side effects: 48% vs 12%, p = 0.0055). The total hospitalization cost of the VEN group was significantly less than that of the IC group ( p = 0.0395). Conclusion: In conclusion, our study indicated that VEN + AZA with a higher MRD-negative remission rate and less toxic appeared to be a therapy option for young patients with ND AML. However, further well-designed studies with larger numbers of patients are needed to confirm the benefits of VEN + AZA in this population.https://doi.org/10.1177/20406207241311776 |
| spellingShingle | Xuezhu Xu Rui Liu Hongli Chen Ruoyu Yang Gongzhizi Gao Aili He Fangxia Wang Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia Therapeutic Advances in Hematology |
| title | Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia |
| title_full | Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia |
| title_fullStr | Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia |
| title_full_unstemmed | Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia |
| title_short | Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia |
| title_sort | single center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia |
| url | https://doi.org/10.1177/20406207241311776 |
| work_keys_str_mv | AT xuezhuxu singlecenterexperienceofvenetoclaxcombinedwithazacitidineinyoungpatientswithnewlydiagnosedacutemyeloidleukemia AT ruiliu singlecenterexperienceofvenetoclaxcombinedwithazacitidineinyoungpatientswithnewlydiagnosedacutemyeloidleukemia AT honglichen singlecenterexperienceofvenetoclaxcombinedwithazacitidineinyoungpatientswithnewlydiagnosedacutemyeloidleukemia AT ruoyuyang singlecenterexperienceofvenetoclaxcombinedwithazacitidineinyoungpatientswithnewlydiagnosedacutemyeloidleukemia AT gongzhizigao singlecenterexperienceofvenetoclaxcombinedwithazacitidineinyoungpatientswithnewlydiagnosedacutemyeloidleukemia AT ailihe singlecenterexperienceofvenetoclaxcombinedwithazacitidineinyoungpatientswithnewlydiagnosedacutemyeloidleukemia AT fangxiawang singlecenterexperienceofvenetoclaxcombinedwithazacitidineinyoungpatientswithnewlydiagnosedacutemyeloidleukemia |